Aviceda Therapeutics to advance eye disease drug despite Phase IIb loss
Aviceda Therapeutics’ eye disease drug will advance to Phase III, despite it failing to meet the primary endpoint in a…
Latest News
-
-
Immunome seeks GSI inhibitor market entry on Phase III desmoid tumour win
Immunome is seeking US approval for its gamma secretase inhibitor (GSI) for the treatment of desmoid tumours after the drug…
-
InnoCare’s BTK inhibitor advances to Phase III in SLE
InnoCare Pharma’s orelabrutinib is progressing to a pivotal trial in systemic lupus erythematosus (SLE) after the drug displayed encouraging activity…
-
Lilly’s triple G agonist boasts 28.7% weight loss in Phase III trial
Eli Lilly’s triple glucagon agonist has achieved up to 28.7% weight loss in a Phase III trial. In the TRIUMPH-4…
-
GRI Bio’s tazarotene achieves Phase IIa IPF success
GRI Bio’s lead candidate, tazarotene, has exhibited disease-modifying potential in a mid-stage study in idiopathic pulmonary fibrosis (IPF). In the…
-
BioNTech and BMS’ bispecific touts 59.3% nine-month PFS in TNBC
Bristol Myers Squibb (BMS) and BioNTech's pumitamig has displayed promising efficacy and safety during a mid-stage trial in front and…
-
Roche posts second Phase III win for oral SERD
Roche’s oral selective oestrogen receptor degrader (SERD) has reduced the risk of invasive disease recurrence or death by 30% in…
-
Dyne to seek accelerated approval of DMD drug on Phase I/II data
Dyne Therapeutics is seeking US accelerated approval of its Duchenne muscular dystrophy (DMD) drug after it met its endpoints in…
-
ASH 2025: MSD’s B-ALL drug shows potential, but all patients experience AEs
MSD said its newly acquired T-cell engager has demonstrated acceptable tolerability and safety in relapsed or refractory B-cell acute lymphoblastic…
-
Kallyope’s migraine drug advances to pivotal trial
Kallyope is advancing its lead migraine drug to pivotal trials after it has shown to be competitive with marketed therapies…
